We are an oncology-focused company seeking to develop and commercialize next
generation targeted small molecule drug candidates for cancer treatment. Our
primary investment is focused on the development of our proprietary targeted
cancer drug candidates, including CUDC-907, an oral, small molecule drug
candidate that is designed to inhibit histone deacetylase or HDAC and
phosphatidylinositol-3-kinase, or PI3K enzymes and CUDC-427, an oral, small
molecule drug candidate, which is designed to promote cancer cell death by
antagonizing inhibitor of apoptosis, or IAP proteins. Our collaborators F.
Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of
the Roche Group, are commercializing and continuing the further development of
Erivedge� (vismodegib), a first-in-class orally-administered small molecule
Hedgehog pathway inhibitor, and our licensee Debiopharm S.A.